One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Catching fibrosis in motion: time-dependent diffusion MRI-derived cell diameter reveals the transitional state of intestinal scarring in Crohn’s disease
doi : 10.1093/ecco-jcc/jjaf146
Volume 19, Issue 8, August 2025
Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale
doi : 10.1093/ecco-jcc/jjaf147
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
doi : 10.1093/ecco-jcc/jjaf129
Longitudinal profiles of fecal calprotectin and C-reactive protein in relation to outcomes in Crohn’s disease patients on infliximab
doi : 10.1093/ecco-jcc/jjaf120
Recombinant herpes zoster vaccine lowers shingles complication risk in patients with inflammatory bowel disease
doi : 10.1093/ecco-jcc/jjaf116
Magnetic resonance cell size imaging reveals intestinal fibrosis to predict intestinal disease progression in patients with Crohn’s disease
doi : 10.1093/ecco-jcc/jjaf119
Spatiotemporal analysis of Crohn’s disease reveals PECAM2 signaling at the basis of the inflammation-to-fibrosis transition
doi : 10.1093/ecco-jcc/jjaf130
Early reduction in rectal wall thickness on transperineal ultrasound predicts mucosal healing in ulcerative colitis
doi : 10.1093/ecco-jcc/jjaf141
Machine learning for predicting Crohn’s disease from routine blood tests years before diagnosis: results from the epi-IIRN cohort
doi : 10.1093/ecco-jcc/jjaf143
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study
doi : 10.1093/ecco-jcc/jjaf151
Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials
doi : 10.1093/ecco-jcc/jjaf145
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension study
doi : 10.1093/ecco-jcc/jjaf138
Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?
doi : 10.1093/ecco-jcc/jjaf144
Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study
doi : 10.1093/ecco-jcc/jjaf123
